Adverse effects of immune checkpoint inhibitors used to treat melanoma and other cancer

Monoclonal antibodies targeted against the immune checkpoint molecules CTLA-4 and PD-1 have recently obtained approval for the treatment of metastatic melanoma and advanced/refractory non small-cell lung cancers and metastatic renal cancer. Besides their efficacy profile, these immune targeted agent...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	La Presse médicale (1983) 2017-09, Vol.46 (9), p.808-817
Hauptverfasser:	Jacquin-Porretaz, Claire, Nardin, Charlée, Puzenat, Eve, Roche-Kubler, Blandine, Aubin, François
Format:	Artikel
Sprache:	fre
Schlagworte:	Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - genetics Carcinoma, Renal Cell - pathology CTLA-4 Antigen - antagonists & inhibitors CTLA-4 Antigen - genetics Genes, cdc - drug effects Guideline Adherence Immunotoxins - adverse effects Immunotoxins - therapeutic use Kidney Neoplasms - drug therapy Kidney Neoplasms - genetics Kidney Neoplasms - pathology Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Melanoma - drug therapy Melanoma - genetics Neoplasm Metastasis Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - genetics Skin Neoplasms - drug therapy Skin Neoplasms - genetics Skin Neoplasms - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!